https://mindmedicinelaw.com/briefing/fda-s-comp360-approval-path-implications-for-psychedelics-20260608-11286The Psychedelic Journalen2026-06-08T22:04:13.815212+00:00FDA's COMP360 Approval Path: Implications for PsychedelicsFDA approval, COMP360, REMS, psilocybin therapy, psychedelic industry, regulatory process, investor implications, clinical trials, risk management, psychedelic researchhttps://mindmedicinelaw.com/briefing/french-study-examines-psilocybin-from-red-light-holland-20260608-11131The Psychedelic Journalen2026-06-08T15:04:30.772947+00:00French Study Examines Psilocybin from Red Light Hollandpsilocybin research, French brain study, Red Light Holland, psychedelic trials, commercial suppliers, international research, brain effects, policy implications, neuroscience, clinical applicationshttps://mindmedicinelaw.com/briefing/psychedelic-therapy-pilot-shows-promise-for-depression-20260608-11130The Psychedelic Journalen2026-06-08T15:04:21.191708+00:00Psychedelic Therapy Pilot Shows Promise for Depressionpsychedelic therapy, clinical depression, pilot trial, mental health treatment, psilocybin, serotonin receptors, treatment protocols, psychiatric research, safety and efficacy, regulatory considerationhttps://mindmedicinelaw.com/briefing/psilocybin-s-potential-in-adhd-neuroplasticity-insights-20260605-11119The Psychedelic Journalen2026-06-08T15:04:49.416717+00:00Psilocybin's Potential in ADHD: Neuroplasticity Insightspsilocybin, ADHD, neuroplasticity, prenatal stress, clinical trials, psychedelic research, mental health, neuroscience, therapeutic potentialhttps://mindmedicinelaw.com/briefing/cross-national-psychedelic-use-study-icps-findings-20260605-10743The Psychedelic Journalen2026-06-07T15:03:15.224139+00:00Cross-National Psychedelic Use Study: ICPS Findingspsychedelic use, ICPS study, psilocybin, LSD, MDMA, ketamine, clinical trials, therapeutic guidelines, adverse health effects, nonmedical usehttps://mindmedicinelaw.com/briefing/ketamine-and-esketamine-for-resistant-depression-a-systematic-review-20260605-10754The Psychedelic Journalen2026-06-07T15:03:07.270035+00:00Ketamine and Esketamine for Resistant Depression: A Systematic Reviewketamine, esketamine, treatment-resistant depression, rapid antidepressant effects, clinical trials, mental health policy, NMDA receptor antagonists, long-term safety, healthcare utilizationhttps://mindmedicinelaw.com/briefing/therapeutic-alliance-in-psilocybin-therapy-for-depression-20260604-11055The Psychedelic Journalen2026-06-08T15:04:41.054969+00:00Therapeutic Alliance in Psilocybin Therapy for Depressiontherapeutic alliance, psilocybin therapy, treatment-resistant depression, ego dissolution, psychedelic therapy, clinical outcomes, psychotherapy integration, depression treatment, mental health, clinical trialshttps://mindmedicinelaw.com/briefing/cannabis-cue-task-shows-no-neural-differences-across-cud-risk-groups-20260603-10086The Psychedelic Journalen2026-06-07T15:03:41.193426+00:00Cannabis Cue Task Shows No Neural Differences Across CUD-Risk Groupscannabis use disorder, neural differences, inhibitory control, prefrontal activation, CUDIT-R, functional near-infrared spectroscopy, behavioral tasks, diagnostic tools, clinical practice, neural adaptationshttps://mindmedicinelaw.com/briefing/ketogenic-therapy-in-anorexia-nervosa-promising-trial-results-20260603-10087The Psychedelic Journalen2026-06-07T15:03:32.875594+00:00Ketogenic Therapy in Anorexia Nervosa: Promising Trial Resultsketogenic therapy, anorexia nervosa, psychiatric disorder, eating disorder treatment, clinical trial, dietary intervention, symptom management, public health, neuroscience, feasibility studyhttps://mindmedicinelaw.com/briefing/bnst-activity-in-alcohol-abstinence-implications-for-aud-treatment-20260603-10136The Psychedelic Journalen2026-06-07T15:03:23.781723+00:00BNST Activity in Alcohol Abstinence: Implications for AUD TreatmentBNST activity, alcohol use disorder, AUD treatment, neurobiology, abstinence, aversion-resistant intake, dBNST, phenotype-specific adaptations, operant task, calcium transientshttps://mindmedicinelaw.com/briefing/gut-brain-axis-in-anxiety-and-depression-new-insights-20260602-10733The Psychedelic Journalen2026-06-07T15:03:51.475735+00:00Gut-Brain Axis in Anxiety and Depression: New Insightsgut-brain axis, anxiety disorders, depression, probiotics, dietary interventions, mental health, dysbiosis, neuroscience, clinical trials, public healthhttps://mindmedicinelaw.com/briefing/nitrous-oxide-abuse-b12-deficiency-neuro-risks-20260528-10109The Psychedelic Journalen2026-06-07T22:04:13.481652+00:00Nitrous Oxide Abuse: B12 Deficiency & Neuro Risksnitrous oxide abuse, vitamin B12 deficiency, neurological damage, public health concern, recreational drug use, neurotoxicity, clinical intervention, myeloneuropathy, cognitive disorders